Activation of ABL1 kinase in NSCLC and breast cancer malignancies has been shown to occur downstream of the EGFR, human epidermal growth factor receptor 2 (HER2), and IGFR, as a late occurring event that contributes to the aggressive growth and metastasis of these solid tumors [31, 52, 53]. Here, ERBB2 is linked to breast carcinoma.